Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

BACKGROUND: Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and its relationship with clinical outcome in the real-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurkmans, Daan P., Sassen, Sebastiaan D.T., de Joode, Karlijn, Putter, Lisanne, Basak, Edwin A., Wijkhuijs, Annemarie J.M., Joerger, Markus, Debets, Reno, Koch, Birgit C.P., Van der Leest, Cor H., Schreurs, Marco W.J., van der Veldt, Astrid A.M., Aerts, Joachim G.J.V., Mathijssen, Ron H.J., Koolen, Stijn L.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183294/
https://www.ncbi.nlm.nih.gov/pubmed/34088739
http://dx.doi.org/10.1136/jitc-2021-002344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183294/
https://www.ncbi.nlm.nih.gov/pubmed/34088739
http://dx.doi.org/10.1136/jitc-2021-002344

Ejemplares similares